-
1
-
-
0004069412
-
Draft guidance for industry: Food-effect bioavailability and bioequivalence studies
-
Anonymous US department of health and human services, Food and drug administration, CDER
-
Anonymous 1997 Draft guidance for industry: food-effect bioavailability and bioequivalence studies. US department of health and human services, Food and drug administration, CDER
-
(1997)
-
-
-
2
-
-
0242700681
-
Note for guidance on modified release oral and transdermal dosage forms: Section II (pharmacokinetic and clinical evaluation)
-
Anonymous The European Agency for the evaluation of medicinal products, CPMP/EWP/280/96
-
Anonymous 1999 Note for guidance on modified release oral and transdermal dosage forms: Section II (pharmacokinetic and clinical evaluation). The European Agency for the evaluation of medicinal products, CPMP/EWP/280/96
-
(1999)
-
-
-
3
-
-
0003484310
-
Draft guidance for industry: Bioanalytical method validation
-
Anonymous US department of health and human services, Food and drug administration, CDER, CVM
-
Anonymous 2001 Draft guidance for industry: bioanalytical method validation. US department of health and human services, Food and drug administration, CDER, CVM
-
(2001)
-
-
-
4
-
-
0032749958
-
Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation
-
Chung M, Vashi V, Puente J, Sweeney M, Meredith PA 1999 Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 48: 678-687
-
(1999)
Br J Clin Pharmacol
, vol.48
, pp. 678-687
-
-
Chung, M.1
Vashi, V.2
Puente, J.3
Sweeney, M.4
Meredith, P.A.5
-
5
-
-
0023771513
-
Nifedipine: Individual responses and concentration-effect relationships
-
Donnelly R, Elliott HL, Meredith PA, Kelman AW, Reid JL 1988 Nifedipine: individual responses and concentration-effect relationships. Hypertension 12: 443-449
-
(1988)
Hypertension
, vol.12
, pp. 443-449
-
-
Donnelly, R.1
Elliott, H.L.2
Meredith, P.A.3
Kelman, A.W.4
Reid, J.L.5
-
6
-
-
0028235611
-
Concentration-effect analysis of antihypertensive drug response - Focus on calcium antagonists
-
Donnelly R, Elliott HL, Meredith PA 1994 Concentration-effect analysis of antihypertensive drug response - focus on calcium antagonists. Clin Pharmacokinetic 26: 472-485
-
(1994)
Clin Pharmacokinetic
, vol.26
, pp. 472-485
-
-
Donnelly, R.1
Elliott, H.L.2
Meredith, P.A.3
-
7
-
-
0030045954
-
The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties
-
Grund JS, Foster RT 1996 The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin Pharmacokinet 30: 28-51
-
(1996)
Clin Pharmacokinet
, vol.30
, pp. 28-51
-
-
Grund, J.S.1
Foster, R.T.2
-
8
-
-
0028966473
-
In vitro and in vivo evaluation of a once-daily controlled-release pseudoephedrine product
-
Hwang SS, Gorsline J, Louie J, Dye D, Guinta D, Hamel L 1995 In vitro and in vivo evaluation of a once-daily controlled-release pseudoephedrine product. J Clin Pharmacol 35: 259-267
-
(1995)
J Clin Pharmacol
, vol.35
, pp. 259-267
-
-
Hwang, S.S.1
Gorsline, J.2
Louie, J.3
Dye, D.4
Guinta, D.5
Hamel, L.6
-
9
-
-
0021931030
-
Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle
-
Karim A, Burns T, Wearly L, Streicher J, Palmer M 1985a Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle. Clin Pharmacol Ther 38: 77-83
-
(1985)
Clin Pharmacol Ther
, vol.38
, pp. 77-83
-
-
Karim, A.1
Burns, T.2
Wearly, L.3
Streicher, J.4
Palmer, M.5
-
10
-
-
0022392154
-
Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption
-
Karim A, Burns T, Janky D, Hurwitz A 1985b Food-induced changes in theophylline absorption from controlled-release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption. Clin Pharmacol Ther 38: 642-647
-
(1985)
Clin Pharmacol Ther
, vol.38
, pp. 642-647
-
-
Karim, A.1
Burns, T.2
Janky, D.3
Hurwitz, A.4
-
11
-
-
0021237346
-
Nifedipine: Kinetics and dynamics in healthy subjects
-
Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD 1984 Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 35: 742-749
-
(1984)
Clin Pharmacol Ther
, vol.35
, pp. 742-749
-
-
Kleinbloesem, C.H.1
van Brummelen, P.2
van de Linde, J.A.3
Voogd, P.J.4
Breimer, D.D.5
-
12
-
-
0023145387
-
Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans
-
Kleinbloesem CH, van Brummelen P, Danhof M, Faber H, Urquhart J, Breimer DD 1987 Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 47: 26-30
-
(1987)
Clin Pharmacol Ther
, vol.47
, pp. 26-30
-
-
Kleinbloesem, C.H.1
van Brummelen, P.2
Danhof, M.3
Faber, H.4
Urquhart, J.5
Breimer, D.D.6
-
13
-
-
4344566603
-
Dihydropyridine calcium channel blockers: Basic pharmacological similarities but fundamental therapeutic differences
-
Meredith PA, Elliott HL 2004 Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences. J Hypertens 22: 1641-1648
-
(2004)
J Hypertens
, vol.22
, pp. 1641-1648
-
-
Meredith, P.A.1
Elliott, H.L.2
-
14
-
-
0035987168
-
The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: Pronounced lag-time after a high fat breakfast
-
Schug BS, Brendel E, Chantraine E, Wolf D, Martin W, Schall R, Blume HH 2002a The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Br J Clin Pharmacol 53: 582-588
-
(2002)
Br J Clin Pharmacol
, vol.53
, pp. 582-588
-
-
Schug, B.S.1
Brendel, E.2
Chantraine, E.3
Wolf, D.4
Martin, W.5
Schall, R.6
Blume, H.H.7
-
15
-
-
0036118842
-
Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union
-
Schug BS, Brendel E, Wolf D, Wonnemann M, Wargenau M, Blume HH 2002b Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur J Pharm Sci 15: 279-285
-
(2002)
Eur J Pharm Sci
, vol.15
, pp. 279-285
-
-
Schug, B.S.1
Brendel, E.2
Wolf, D.3
Wonnemann, M.4
Wargenau, M.5
Blume, H.H.6
-
16
-
-
85019292399
-
Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast
-
Schug BS, Brendel E, Wonnemann M, Wolf D, Wargenau M, Dingler A, Blume HH 2002c Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur J Clin Pharmacol 58: 119-125
-
(2002)
Eur J Clin Pharmacol
, vol.58
, pp. 119-125
-
-
Schug, B.S.1
Brendel, E.2
Wonnemann, M.3
Wolf, D.4
Wargenau, M.5
Dingler, A.6
Blume, H.H.7
-
18
-
-
30644473558
-
Nifedipine extended release tablet/BAY a 1040/calcium antagonist Investigator's brochure/Bayer AG
-
Wagener G 2001 Nifedipine extended release tablet/BAY a 1040/calcium antagonist Investigator's brochure/Bayer AG: 8: 1-55
-
(2001)
, vol.8
, pp. 1-55
-
-
Wagener, G.1
-
19
-
-
33646671392
-
Multisource (Generic) Pharmaceutical Products: Draft Guideline on Registration Requirements to establish interchangeability
-
World Health Organization QAS/04.093
-
World Health Organization 2004 Multisource (Generic) Pharmaceutical Products: Draft Guideline on Registration Requirements to establish interchangeability. QAS/04.093
-
(2004)
-
-
|